D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Status:
Not yet recruiting
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety and efficacy of administering a
single intracerebral (within the brain) dose of investigational compounds called
D2C7-immunotoxin (IT) and 2141-V11 in residual disease (within tumor margins) after surgery,
followed by later repeated injections of 2141-V11 in the subcutaneous area (under the skin)
around the lymph nodes of the head and neck for adults newly diagnosed with a type of
cancerous brain tumor called glioblastoma. The word "investigational" means the study drugs
are still being tested in research studies and are not approved by the U.S. Food and Drug
Administration (FDA).